<DOC>
	<DOCNO>NCT02044692</DOCNO>
	<brief_summary>The objective study evaluate long term safety efficacy weekly dose idurasulfase-beta 0.5mg/kg administered Hunter Syndrome ( Mucopolysaccharidosis II ) Patients</brief_summary>
	<brief_title>The Long-term Safety Study Idursulfase-beta Hunter Syndrome ( Mucopolysaccharidosis II ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>Patients diagnosis Hunter syndrome ( Mucopolysaccharidosis II ) . Patients administer idurasulfasebeta willing administer idurasulfasebeta . Patient 's parent ( ) , patient 's legal guardian must give voluntary write consent participate study . Patients participate blind clinical trial . Patient track safety . Patients judge disqualified participate clinical trial investigator cause .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Hunter syndrome</keyword>
	<keyword>Mucopolysaccharidosis II</keyword>
	<keyword>Hunterase</keyword>
</DOC>